

---

## Ascelia Pharma - Time for take-off

Ascelia's Q1 result was minor compared to the recent SPARKLE success. Ascelia is preparing for submission by mid-2025, and Ascelia's cost base was contained. Our Base Case is SEK 17 (Bull SEK 45 and Bear SEK 6).

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

[Ascelia Pharma - Time for take-off](#)